Fabhalta Capsule
Product Images NDC 0078-1189

5 FDA label images from Novartis Pharmaceuticals Corporation · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Fabhalta (NDC 0078-1189). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure Of Iptacopan Hydrochloride Monohydrate (Fabhalta 01)

Chemical Structure Of Iptacopan Hydrochloride Monohydrate (Fabhalta 01)
Chemical structure of iptacopan, the active ingredient in FABHALTA 200 mg capsule. The structure includes labeled stereochemistry and associated hydrochloride and hydrate moieties as shown.*
FDA Label Image

Figure 1: Geometric Mean Percent Change From Baseline In Upcr [fmv] And 24-hour Upcr By Visit In Applause-igan (Fabhalta 03)

Figure 1: Geometric Mean Percent Change From Baseline In Upcr [fmv] And 24-hour Upcr By Visit In Applause-igan (Fabhalta 03)
A line graph showing the geometric mean percent change from baseline over 24 months for FABHALTA 200 mg bid versus placebo. The graph includes UPCR-FMV and 24-hour UPCR data, with FABHALTA groups in red showing a downward trend and placebo groups in blue showing stable or slightly increasing values. Time is on the x-axis (months) and percent change on the y-axis. Sample sizes for each group at various time points are indicated below.*
FDA Label Image

Figure 2: Mean Change From Baseline In Egfr (ml/min/1.73 M²) By Visit In Applause-igan (Fabhalta 05)

Figure 2: Mean Change From Baseline In Egfr (ml/min/1.73 M²) By Visit In Applause-igan (Fabhalta 05)
A line graph showing mean change from baseline over 24 months for FABHALTA 200 mg and placebo groups. The x-axis represents time in months, and the y-axis shows mean change from baseline with 95% confidence intervals. FABHALTA 200 mg is represented by a red solid line, and placebo by a blue dashed line, each with data points and error bars. Patient numbers for each group at various time points are listed below the graph.*
FDA Label Image

Figure 3: Geometric Mean Percent Change From Baseline In Upcr Fmv (g/g) Up To Month 12 (appear-c3g) (Fabhalta 04)

Figure 3: Geometric Mean Percent Change From Baseline In Upcr Fmv (g/g) Up To Month 12 (appear-c3g) (Fabhalta 04)
A line graph depicting percentage change with 95% confidence intervals over time (days) comparing FABHALTA (iptacopan) and placebo during double-blind and open-label periods. The x-axis shows visit days from baseline (BL) to day 360, and the y-axis shows the percentage change. FABHALTA shows a notable decline in percentage change, while placebo remains near baseline during the double-blind period. The graph includes data points for FABHALTA switch and placebo groups.*
FDA Label Image

Principal Display Panel Ndc 0078-1189-20 Rx Only Fabhalta® (iptacopan) Capsules 200 mg Dispense With Accompanying Medication Guide. 60 Capsules Swallow The Capsules Whole. Do Not Open, Break, Or Chew Capsules. Novartis (Fabhalta 02)

Principal Display Panel								Ndc 0078-1189-20								Rx Only								Fabhalta®								(iptacopan) Capsules								200 mg								Dispense With Accompanying Medication Guide.								60 Capsules								Swallow The Capsules Whole. Do Not Open, Break, Or Chew Capsules.								Novartis (Fabhalta 02)
The label for FABHALTA (iptacopan) capsules 200 mg by Novartis Pharmaceuticals Corporation. It indicates 60 capsules in the package with instructions to swallow whole, storage temperature guidance, and manufacturer information from Novartis Pharma Produktions GmbH, Slovenia. Includes the NDC 0078-1189 and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.